Invesco Nasdaq Biotechnology ETF closed at $35.82 on Nov 12, down 2.32%, 2.8% below its 52-week closing high. Volume of 34.6K shares was 0.53× its 20-day average (below normal).
Split-adjusted performance: +5.6% over one month, +20.4% over six months, +30.2% over one year.
In the quarter ended Sep 30, 2026, revenue was $1.87B, up 14.2% from a year earlier, with a net margin of 15.7%.
Short interest was 47.0K shares at the Oct 30 settlement, up 39.5% from the prior report (1.1 days to cover).